AIA
PLX icon

Alera Investment Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Alera Investment Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed – – 757
2019
Q1 		$0 Hold
100
– – ﹤0.01% 1297
2018
Q4 		$0 Buy
+100
New +$475 ﹤0.01% 1164

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Alera Investment Advisors's PLX Position: Q2 2019 in Review

Alera Investment Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2019, closing a stake of 100 shares.

Alera Investment Advisors first reported a position in PLX in Q4 2018 and held it in 2 quarters. The position peaked at $0 in Q1 2019. 31 funds tracked by Wall St. Rank hold PLX as of Q2 2019.

  • Alera Investment Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 100 Protalix BioTherapeutics shares in Q2 2019.
  • Alera Investment Advisors first reported a position in Protalix BioTherapeutics in Q4 2018 and held it in 2 quarters.
  • Alera Investment Advisors's Protalix BioTherapeutics position peaked at $0 in Q1 2019.
  • 31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2019.

Based on Alera Investment Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.